Description

Simple

Clinical

Overview

Abexinostat has been used in trials studying the treatment of Sarcoma, Lymphoma, Leukemia, Lymphocytic, and Hodgkin Disease, among others. It is a novel, broad-spectrum hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity.

Pharmacology

Indication

Information currently not available.

Pharmacodynamic

Information currently not available.

Mechanism of action

Abexinostat is a novel histone deacetylase (HDAC) inhibitor. HDAC inhibitors target HDAC enzymes and inhibit the proliferation of cancer cells and induce cancer cell death, or apoptosis. Histone deacetylation is carried out by a family of related HDAC enzymes. Inhibition of these enzymes causes chan... Read more

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Information currently not available.

Route of elimination

Information currently not available.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Abexinostat
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
Acebutolol
The risk or severity of QTc prolongation can be increased when Acebutolol is combined with Abexinostat.
Aceprometazine
The risk or severity of QTc prolongation can be increased when Aceprometazine is combined with Abexinostat.
Acetyldigoxin
The risk or severity of QTc prolongation can be increased when Acetyldigoxin is combined with Abexinostat.
Acrivastine
The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Abexinostat.
Adenosine
The risk or severity of QTc prolongation can be increased when Adenosine is combined with Abexinostat.
Ajmaline
The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Abexinostat.
Alfuzosin
The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Abexinostat.
Alimemazine
The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Abexinostat.
Amantadine
The risk or severity of QTc prolongation can be increased when Amantadine is combined with Abexinostat.
Amifampridine
The risk or severity of QTc prolongation can be increased when Amifampridine is combined with Abexinostat.
Amiodarone
The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Amiodarone.
Amisulpride
The risk or severity of QTc prolongation can be increased when Amisulpride is combined with Abexinostat.
Amitriptyline
The risk or severity of QTc prolongation can be increased when Amitriptyline is combined with Abexinostat.
Amodiaquine
The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Abexinostat.
Amoxapine
The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Abexinostat.
Anagrelide
The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Anagrelide.
Anisodamine
The risk or severity of QTc prolongation can be increased when Anisodamine is combined with Abexinostat.
Antazoline
The risk or severity of QTc prolongation can be increased when Antazoline is combined with Abexinostat.
Apomorphine
The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Abexinostat.
Aranidipine
The risk or severity of QTc prolongation can be increased when Aranidipine is combined with Abexinostat.
1 References
  1. 1 . Buggy JJ, Cao ZA, Bass KE, Verner E, Balasubramanian S, Liu L, Schultz BE, Young PR, Dalrymple SA: CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo. Mol Cancer Ther. 2006 May;5(5):1309-17.PubMed: 16731764